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Abstract
Progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are progressive disabling neurological conditions
usually fatal within 10 years of onset. Little is known about the economic costs of these conditions. This paper reports
service use and costs from France, Germany and the UK and identifies patient characteristics that are associated with cost.
767 patients were recruited, and 760 included in the study, from 44 centres as part of the NNIPPS trial. Service use during
the previous six months was measured at entry to the study and costs calculated. Mean six-month costs were calculated for
742 patients. Data on patient sociodemographic and clinical characteristics were recorded and used in regression models to
identify predictors of service costs and unpaid care costs (i.e., care from family and friends). The mean six-month service
costs of PSP were J24,491 in France, J30,643 in Germany and J25,655 in the UK. The costs for MSA were J28,924, J25,645
and J19,103 respectively. Unpaid care accounted for 68–76%. Formal and unpaid costs were significantly higher the more
severe the illness, as indicated by the Parkinson’s Plus Symptom scale. There was a significant inverse relationship between
service and unpaid care costs.
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Introduction
Progressive supranuclear palsy (PSP) and multiple system
atrophy (MSA) are rare progressive neurodegenerative disorders,
usually presenting as akinetic-rigid syndromes (‘parkinson plus
syndromes’). Age at onset is typically between 55 and 65, and the
average life expectancy from onset is 5–10 years for both diseases
[1–8]. The prevalence of each of these disorders has been
estimated at 2–7 per 100,000 [4,5,9–15], although this is likely to
be an underestimate because of diagnostic confusion with
idiopathic Parkinson’s disease. The number of people aged 55 or
above with PSP has been estimated at 14–25 per 100,000, with a
figure of 17–29 per 100,000 for MSA [5,10]. Given that there are
approximately 177 million people aged 55 or over in the 27
countries of the EU [16] this translates to 25,000–44,000 with PSP
and 30,000–51,000 with MSA.
Patients with MSA and PSP require care from a range of
services, and it is likely that such inputs will need to increase as the
disease progresses. However, to date there have been no attempts
to comprehensively measure and cost service use for patients.
Measures of costs for a representative sample of patients allow us
to determine relationships between care inputs and patient needs,
assess the cost-effectiveness of specific treatments and highlight the
impact that these conditions have on society as a whole.
As part of the NNIPPS study [17] we adapted a health service
use questionnaire [18] to estimate the resource use associated with
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the UK). This paper reports the service use and cost for patients at
entry to the study and identifies predictors of the costs.
Methods
Ethics approval
Patients gave written consent prior to participating in the study.
The protocol and amendments were reviewed and approved by
the Comite ´ de Protection des Personnes of Pitie ´-Salpe ˆtrie `re
Hospital (France), the UK Multicentre Research Ethics Commit-
tee (MREC), (UK), Ethikkommission of the University of Ulm,
(Germany), and by local Institutional Review Boards (Ethics
Committees) where appropriate (UK, Germany). These include,
UK: Ethics committees of Belfast, Birmingham - City Hospital,
Birmingham - Queen Elizabeth Hospital, Cambridge, Liverpool,
King’s College London, NHNN & Queen Square Hospital,
Newcastle upon Tyne, Stafford, Aberdeen, Guernsey, Swansea.
Germany: Aachen, Berlin, Bochum, Dresden, Freiburg, Halle,
Hannover, Magdeburg, Mu ¨nchen, Regensburg, Rostock, Tu ¨bin-
gen, Ulm.
The broad aims of the NNIPPS project were to evaluate the use
of riluzole, a potential neuroprotector and to assess the natural
history of PSP and MSA. Details of the inclusion criteria and study
design are published elsewhere [17]. Briefly, patients with an
akinetic-rigid syndrome diagnosed as PSP or MSA according to
the NNIPPS diagnostic criteria were eligible. The intention to
treat (ITT) population comprised of 760 patients (362 PSP and
398 MSA) recruited in 44 centres in the UK, France and
Germany. Patients were stratified according to diagnosis and
randomised double-blind to riluzole or placebo. The primary
efficacy measure was survival, and secondary endpoints included
rate of change in functional scores.
Patients were to be followed-up 3-monthly for three years for
safety assessment. For efficacy and natural history assessment, the
following measures were completed at entry to the study (between
2000 and 2002) and used in the subsequent economic analyses: (i)
demographic characteristics (including age, gender, ethnicity,
education), (ii) vital signs (including weight and height), (iii) Hoehn
and Yahr disease staging scale (HYS) [19], (iv) a Short Motor
Disability Scale (SMDS) [21], (v) Clinical Global Impression of
Disease Severity (CGI)-ds [20], (vi) Parkinson Plus Symptoms scale
(NNIPPS-PPS) [21], (vii) Short-Form 36 [22], (viii) Client Service
Receipt Inventory (CSRI) [18]. SMDS was completed at follow-up
3-montly, HYS, CGI-ds, PPS, 6-monthly, and SF36 and CSRI 6-
monthly the first year then 12-monthly.
Service use and costs
It is important in any economic study to include information on
all services that may be used because of the specific condition
under investigation. Service use during the six-month period prior
to interview was measured using the Client Service Receipt
Inventory (CSRI) adapted for these disorders (Appendix S1).
Participants were asked for information on their use of hospital
and community services, i.e. whether they used them, how many
times and (where relevant) for the average duration of contacts.
They were also asked to provide details of any scans or tests they
had received in the six-month period, whether they had been
provided with any prostheses (wheelchairs, walking frames, etc),
and whether any adaptations had been made to their home
because of their illness. Further information was sought on care
provided because of the illness by family members or friends and
any impact that the illness had on employment of the patients
themselves or members of their families.
Unit costs were attached to the service use measures in order to
generate service costs and were obtained from a number of
sources. UK unit costs were taken from a recognised national
source [23]. Figures for most services in France and Germany
were obtained from Medtap International [24]. A small number of
costs were not available and therefore they were based on the costs
from other countries and adjusted using ratios between the
countries for costs that were available. Most figures from the UK
represented actual costs whilst those provided by Medtap
International represented a mixture of costs and charges. Care is
thus required in making comparisons between countries.
The study recorded personal care input from family members
and friends. Whilst care from friends or family members is rarely
paid for, it still represents an important economic cost as the time
spent caring could have been used in alternative activities. We
made the assumption that if the family member or friend was not
providing care then this would have to be provided by services and
consequently we valued unpaid care at the cost of a home care
worker. (Similarly, we could have argued that if the family
member or friend was not caring for the patient then they could in
theory use their skills to provide care in a paid capacity for
someone else.).
Data on medications received were recorded for each patient in
the study. Medication names were entered as free-text variables
and approximately 1000 different names were recorded (some
being the same medications with slightly different spellings or
brand names). A pragmatic approach was taken whereby only
medication taken by at least 1.5% of the sample was costed. The
costs of drugs were obtained where possible from the British
National Formulary (the most common source for such data in the
UK) and combined with medication levels and period of receipt.
Medication costs were subsequently converted to Euros by
dividing by 0.663 (the exchange rate at the time of the study)
[25]. All costs were inflated to 2007/8 prices and UK costs
converted to Euros. The unit costs of specific services used in the
study are shown in Appendix S2.
Analysis
Costs were reported for each country and strata (PSP/MSA)
separately. Tests for significant differences between MSA and PSP
were not conducted at this stage, as there could be differences
between the samples in terms of patient characteristics that might
also influence costs. The existence of significant differences in costs
was, rather, explored using multivariate analyses. Two regression
models were produced. In the first model the dependent variable
was the total service costs excluding unpaid care costs. The second
model used unpaid care costs as the dependent variable. Variables
for inclusion in these two models were chosen because they
described features that pre-disposed clients to use services (age,
gender), features that enabled them to access services (educational
attainment) and features that described their illness (PSP or MSA,
disease duration, cognition, symptom severity) [26]. Cognition was
measured with the MMSE (dichotomised into two groups with
scores 0–27 and 28–30 due to the data distribution) whilst the
NNIPPS-PPS total score was used as a global index of disease
severity. Given the different service systems in each country and
the fact that the unit costs (for reasons described above) may not be
directly comparable, we have conducted separate regression
analyses for each country and controlled for clustering in study
sites.
Cost data are typically positively skewed and this can lead to
similarly skewed residuals representing a violation of one of the
assumptions on which ordinary least squares models are based.
One option for addressing this is to use bootstrapping methods
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However, the need for modelling the actual data distribution has
been advocated [27]. We have here used a general linear model
and specified that the data follow a gamma distribution (which cost
data frequently do) and also specified a log link function. This
allowed the proportional impact of a unit change in the
independent variables on cost to be assessed which was more
appropriate than assessing the direct impact given that we were
analysing data from quite different service systems.
Results
Of the 760 patients in the ITT cohort usable data on service use
was available at baseline for 742 participants (PSP n=352, MSA
n=390). Population characteristics are shown in Table 1. The
mean age was similar for all countries, and in each the PSP
patients tended to be slightly older. In the UK there were relatively
fewer women in the sample compared to France and Germany.
Clinical characteristics (disease duration and severity) were very
similar for PSP and MSA patients and in each country.
There were some similarities across the three countries in the
use of services by patients with PSP (Table 2). The majority of
patients had contacts with neurologists and around one-third with
other specialists during the six-month period, and most had
contacts with general practitioners. Most patients had also had
adaptations to their homes, had prostheses such as wheelchairs or
walking frames and received unpaid care from family or friends.
Almost all received medication. Around one-quarter of patients
spent some time in a residential or nursing home. There were
some country differences to note. Physiotherapists were seen by
around two-thirds of patients in France but by under half in the
UK. Neurology inpatient care was used by relatively more patients
in Germany (although other inpatient care was used by similar
proportions). Social worker and speech therapist contacts were
more likely in the UK. Nurses were seen by around two-thirds of
all patients in France and the UK and fewer in Germany. Patients
in Germany were more likely than those elsewhere to have
received blood tests, EEGs and MRIs. Patients in France were the
least likely to have received unpaid care from family/friends
(although two-thirds still did so). For those receiving specific
services there were also large differences in the number of contacts.
Residential care days were greater in number in Germany and
least in the UK. Contacts with physiotherapists, social workers,
nurses and speech therapists were far greater in both France and
Germany compared to the UK. Of those patients using day care
and home helps, the number of contacts was greatest in the UK.
Patients who were admitted to hospital In France had shorter
lengths of stay than in Germany or the UK. The final row of
Table 2 shows that the mean six-month service costs were similar
in France and the UK and around one-fifth higher in Germany.
There were very similar patterns of service use for patients with
MSA (Table 3). Again, most patients had contacts with
neurologists and general practitioners, and many had contacts
with other specialists. Residential care was used less in Germany.
Most patients received medication and had help from family and
friends. Once again, there were fewer contacts with physiother-
apists, nurses and speech therapists in the UK compared to France
and Germany. The UK patients again had a higher number of day
care contacts than the other countries. Mean six-month costs were
highest in France, followed closely by Germany. Total costs in the
UK were one-third lower in the UK compared to France.
The distribution of service costs (excluding unpaid care from
family/friends) shows that in France, social care accounts for
around one-third of PSP costs whilst in Germany and the UK the
main contributor to PSP costs is inpatient care (Table 4). For MSA
patients, inpatient care is the main contributor to cost in each
country. Medication accounts for a very small amount of cost.
Unpaid care from family/friends accounts for most of the costs.
For PSP the contribution is 68% in France, 73% in Germany and
76% in the UK. For MSA the figures are 76%, 75% and 75%
respectively.
Figures 1 and 2 show the relationship between total mean cost
and symptom severity as measured with the NNIPPS-PPS scale. It
can be seen that costs increase with severity in each country for
PSP patients. This is also generally the case for MSA patients,
although in the UK the patients with the highest severity do not
have the highest costs.
Table 1. Patient characteristics.
France Germany UK
PSP (n=149) MSA (n=158) PSP (n=98) MSA (n=134) PSP (n=105) MSA (n=98)
Age (years), mean (SD) 69.3 (7.3) 63.2 (8.3) 67.3 (5.6) 61.3 (7.5) 66.1 (6.7) 62.0 (9.2)
Female, n (%) 75 (48) 79 (48) 39 (39) 67 (50) 40 (38) 34 (34)
Education, n (%)
Illiterate 3 (2) 4 (3) 0 (0) 0 (0) 0 (0) 0 (0)
Primary school 52 (34) 47 (29) 37 (37) 40 (30) 18 (17) 15 (15)
Secondary school 66 (43) 59 (36) 48 (48) 64 (47) 63 (60) 51 (52)
Higher schooling 17 (11) 19 (12) 5 (5) 9 (7) 13 (12) 16 (16)
University/College 17 (11) 34 (21)) 10 (10) 22 (16) 11 (11) 16 (16)
Clinical Global Impression score, mean (SD) 3.8 (1.0) 3.8 (0.9) 3.7 (1.0) 3.5 (0.9) 3.4 (0.9) 3.4 (1.0)
Short Motor Disability Scale, mean (SD) 6.5 (3.6) 6.4 (3.7) 6.5 (3.9) 5.8(3.8) 6.6 (3.6) 5.9 (3.7)
Disease duration (years), mean (SD) 3.9 (1.7) 4.4 (1.9) 3.9 (1.9) 4.3 (1.8) 4.4 (2.2) 4.8 (2.0)
Hoehn andYahr staging scale, mean (SD) 3.6 (0.9) 3.5 (1.0) 3.7 (1.0) 3.4 (1.1) 3.5 (0.9) 3.4 (1.0)
Parkinson’s Plus Symptom scale, mean (SD) 91.9 (31.3) 87.8 (30.8) 90.3 (29.4) 80.6 (31.0) 92.4 (30.1) 83.4 (30.8)
Mini Mental State Examination, mean (SD) 24.0 (5.4) 26.8 (2.8) 25.7 (4.2) 28.8 (1.9) 25.7 (3.9) 28.0 (2.3)
doi:10.1371/journal.pone.0024369.t001
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unpaidcare from family/friends) reveals that costswere significantly
associated with the NNIPPS-PPS scale, and this relationship was
very similar in each country. In France, a one-unit increase in the
PPS was associated with a 1.9%increase incosts,whilstinGermany
and the UK the figure was 1.7%. In each country there was also an
inverse relationship between formal care and unpaid care costs. If
the latter increase by J1000 then there is a reduction in formal care
costs of 1.2% in France and 1.1% in both Germany and the UK. In
France women had formal care costs that were 35% higher on
average than for men and those with further education had 63%
higher costs than those with the most limited education. In
Germany participants with MMSE scores between 28 and 30 had
costs that were 48% higher than those with lower scores.
Unpaid care costs were also significantly associated with
NNIPPS-PPS scores, with a slightly greater impact of a one-unit
increase in Germany (2.2%) compared to France (1.6%) and the
UK (1.3%). The inverse relationship with formal care costs was
again apparent with similar impacts one a J1000 increase in
France (3.7%), Germany (4.1%) and the UK (3.5%). Secondary
education was associated with significantly lower unpaid care costs
in both France and the UK, with the latter also having
significantly lower costs for patients with a university education.
In France, patients with PSP had significantly lower unpaid care
costs than those with MSA whilst in the UK women had
significantly lower costs than men.
There was no relation between costs, formal or unpaid, and age
or disease duration.
Discussion
This is the first study of the costs of providing care for people
with PSP and MSA, and we have found that patients with PSP and
MSA use a wide range of services and that the mean six-month
costs reported are substantial. Most of the costs are related to
unpaid care. The costs detailed here are for only three countries
and any extrapolation needs to be made with caution. However,
using the lowest and highest costs for PSP (J24491 and J30643)
and for MSA (J19103 and J28924) and the prevalence figures
reported in the introduction suggests annual costs in the 27-
country European Union of J1.2–2.7 billion for PSP and J1.1–
3.0 billion for MSA. These are likely to be underestimates as the
data used in these analyses relate to the six months prior to
inclusion in the study (although average disease duration at that
point was still approximately 4 years).
Service and unpaid family costs were higher for patients with
higher scores on the NNIPPS-PPS which is what we would expect
if resources are more likely to be required by those with greater
levels of symptom severity. This suggests that interventions which
successfully modify disease progression may reduce the economic
burden of these conditions. Data on changes in the NNIPPS-PPS
have been reported elsewhere [21]. If an intervention was able to
Table 2. Service use and costs (2007/8 Js) for patients with progressive supranuclear palsy (PSP).
France Germany UK
Users Contacts
1 Cost
2 Users Contacts
1 Cost
2 Users Contacts
1 Cost
2
N % Mean SD Mean SD N % Mean SD Mean SD N % Mean SD Mean SD
Neurologist 113 77 2.8 2.8 83 117 74 76 4.6 7.3 122 304 85 81 1.8 1.2 425 348
Other doctor 43 29 2.4 2.5 27 68 32 33 1.8 1.1 17 34 39 37 2.4 2.5 123 263
Day patient 24 16 5.7 4.8 278 878 9 9 11.8 13.2 381 1829 11 11 30.8 34.7 936 4157
Residential care 15 10 88.7 79.9 1278 5329 6 6 159.2 42.4 1645 6781 6 6 45.7 60.3 367 2386
Neurology inpat
3 23 15 7.5 11.0 446 1987 49 50 14.9 10.1 2306 3267 14 13 13.3 15.8 827 3361
Other inpat
3 23 15 8.3 10.5 785 3404 16 16 19.1 20.3 1834 6407 20 19 18.2 27.3 1715 6743
GP 135 92 4.8 4.0 113 103 92 94 4.9 4.7 88 101 90 86 3.5 2.8 152 176
Physiotherapist 92 63 55.4 31.4 708 789 58 59 27.5 17.8 467 567 45 43 7.5 10.2 153 389
Social worker 10 7 41.8 66.2 1026 8316 1 1 26.0 - 35 347 30 29 2.8 3.4 91 309
Nurse 44 30 94.0 107.6 314 874 14 14 93.1 143.0 434 2047 35 33 9.9 30.2 65 380
Speech therapist 51 35 31.1 20.3 228 439 21 21 19.4 12.1 145 364 44 42 2.4 2.4 37 71
Home help 47 32 85.0 65.2 1859 5985 11 11 46.6 52.5 158 733 25 24 111.0 114.3 1009 5405
Blood test 73 49 1.7 1.6 21 37 78 79 2.7 3.0 65 88 45 43 2.4 4.2 26 74
CT scan 16 11 1.0 0.0 18 54 16 16 1.1 0.3 19 44 8 8 1.0 0.0 17 60
EEG 17 11 1.0 0.0 5 14 33 33 1.3 0.8 11 20 7 7 1.0 0.0 3 10
MRI 30 20 1.2 0.4 79 173 45 46 1.1 0.4 111 138 29 28 1.1 0.3 133 225
Prostheses 84 54 - - 31 37 52 52 - - 35 42 47 45 - - 29 38
Adaptations 65 42 - - 74 132 48 48 - - 107 143 47 45 - - 82 122
Unpaid care
4 99 66 61.6 64.2 15814 24077 79 81 57.1 51.7 21574 25183 92 88 50.2 48.9 19327 21770
Medication 144 92 - - 195 205 88 87 - - 196 306 89 85 - - 130 207
Total 149 100 - - 24491 25231 98 100 - - 30643 26209 105 100 - - 25655 22823
1Data on contacts are only for those using services,
2Data on costs are for whole sample,
3Contacts refer to number of days,
4Contacts refer to weekly hours.
doi:10.1371/journal.pone.0024369.t002
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PPS scores being 7.5 points lower for PSP and 5.4 points lower for
MSA. While costs will still increase with progression, the
regression models in Tables 5 and 6 suggest that services will be
13–14% lower for PSP and 9–10% lower for MSA. For unpaid
care costs the reductions will be 10–17% and 7–12% lower
respectively.
The costs of unpaid care were significantly lower for women
then men in the UK. Life expectancy and caring roles help to
explain this finding, although it is surprising that it was not
observed in France or Germany. There was an inverse relationship
between unpaid family care costs and service care costs, indicating
that one substitutes for the other (although the percentage change
associated with a J1000 increase is not great. Other variables
were associated with cost but not in a consistent way.
Based on studies using a similar methodology, the six-month
service costs of multiple sclerosis are around £8500 in the UK and
J10000 in Germany [28,29]. Likewise, the six-month costs of
Alzheimer’s disease in the UK is approximately J13000 per
person and schizophrenia J5500 [30,31]. Whilst these figures
indicate the high care needs of PSP and MSA relative to other
conditions, it should be recognised that the total ‘burden’ will be
less given the lower prevalence rates. Of particular interest, and in
common with other degenerative conditions, is the fact that
unpaid family care accounts for most of the cost [32].
There were a number of limitations with the study presented
here. First, in order to measure service use comprehensively it was
necessary to rely on patient self-report, with help from a carer if
necessary. Whilst the schedule used to measure service use is well
developed and has been used in numerous other studies, it may
Table 3. Service use and costs (2007/8 Js) for patients with multiple system atrophy (MSA).
France Germany UK
Users Contacts
1 Cost
2 Users Contacts
1 Cost
2 Users Contacts
1 Cost
2
N % Mean SD Mean SD N % Mean SD Mean SD N % Mean SD Mean SD
Neurologist 137 87 2.8 1.6 99 116 111 83 4.6 4.4 130 169 86 87 1.6 1.2 434 400
Other doctor 49 31 2.2 2.0 27 61 67 50 3.1 2.9 52 98 33 33 2.2 1.4 103 184
Day patient 37 23 4.8 3.8 342 850 4 3 4.8 2.9 51 332 8 8 32.4 42.8 759 4200
Residential care 11 7 94.9 66.9 954 4349 1 1 174.0 - 224 2605 7 7 84.4 89.9 839 4373
Neurology inpat
3 19 12 8.5 7.7 395 1504 51 38 16.5 11.0 1982 3327 15 15 7.7 4.8 547 1554
Other inpat
3 28 18 15.5 33.6 1664 8481 21 16 16.7 16.2 1445 4925 17 17 8.0 8.5 676 2241
GP 145 92 5.1 4.1 126 114 115 86 5.4 7.3 92 161 86 87 3.4 2.9 137 174
Physiotherapist 108 68 54.2 33.2 773 808 104 78 37.8 21.5 864 733 43 43 9.3 11.3 205 490
Social worker 18 11 22.3 53.5 560 4600 4 3 1.5 0.6 3 21 28 28 3.5 3.1 86 207
Nurse 44 28 113.4 128.1 365 1026 11 8 117.3 132.0 321 1626 46 47 11.8 29.3 107 440
Speech therapist 52 33 34.4 24.0 240 500 44 33 21.8 16.2 234 475 37 37 3.4 4.2 59 195
Home help 33 21 88.2 65.2 627 1843 9 7 60.4 52.7 358 2600 13 13 117.1 163.2 347 1219
Blood test 68 43 1.9 2.1 21 43 93 69 2.4 3.1 50 86 44 44 2.0 1.7 22 38
CT scan 11 7 1.0 0.0 13 50 15 11 1.2 0.6 15 46 8 8 1.0 0.0 18 62
EEG 8 5 1.3 0.5 3 13 32 24 1.3 0.8 8 18 6 6 1.2 0.4 3 12
MRI 25 16 1.0 0.2 56 136 41 31 1.1 0.3 72 114 16 16 1.1 0.3 78 183
Prostheses 89 54 - - 35 42 67 50 - - 36 45 45 46 - - 23 31
Adaptations 55 34 - - 76 133 62 46 - - 120 177 35 35 - - 79 144
Unpaid care
4 110 70 77.4 72.2 21130 28581 103 77 49.8 47.6 19036 24049 75 77 42.2 49.4 14186 20639
Medication 157 96 - - 362 334 120 89 - - 317 509 90 91 - - 226 326
Total 158 100 - - 28924 29317 134 100 - - 25645 24284 98 100 - - 19103 21372
1Data on contacts are only for those using services,
2Data on costs are for whole sample,
3Contacts refer to number of days,
4Contacts refer to weekly hours.
doi:10.1371/journal.pone.0024369.t003
Table 4. Distribution of service costs (%).
PSP MSA
Service France Germany UK France Germany UK
Hospital doctor 1.5 1.6 8.7 1.9 2.8 11.3
Day patient 3.7 4.7 14.8 5.1 0.8 16.1
Residential care 16.9 20.2 5.8 14.2 3.5 17.8
Inpatient 16.2 50.7 40.2 30.6 53.4 25.8
GP 1.5 1.1 2.4 1.9 1.4 2.9
Other health
professional
16.5 12.6 4.0 20.5 22.1 7.9
Social care 38.1 2.4 17.4 17.6 5.6 8.9
Investigations/tests 1.6 2.5 2.8 1.4 2.3 2.6
Prostheses/adaptations 1.6 2.2 1.9 1.9 3.1 2.2
Medication 2.5 2.2 2.1 5.1 4.9 4.7
doi:10.1371/journal.pone.0024369.t004
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doi:10.1371/journal.pone.0024369.g001
Figure 2. Total costs by symptom severity based on PPS scale (PSP patients).
doi:10.1371/journal.pone.0024369.g002
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would have led to inaccuracies. A number of studies have
suggested that patient recall of service use can be acceptable [33–
35]. Another study noted a difference between self-report and
administrative records, but pointed out that it was unclear which
was more accurate [36]. Mirandola et al indicate that agreement
between total costs based on self-report and administrative systems
is good, but that special care is required when focussing on
individual cost components [37]. Second, there were within- and
between-country variations in the way in which unit costs were
calculated. Between-country variations were addressed to some
extent by including country variables in the regression models (and
these were not statistically significant). Data for France and
Germany consisted of a mixture of actual costs and charges. It is
unclear to what extent the inclusion of the (second-best) charge
data will have had on the results. If charges were approximately
equal to costs then any effects would be small. Third, this paper
only examines costs and not the quality of care provided. It may be
that some services are not actually having a beneficial impact on
health or quality of life (in which case the costs would be too high)
Table 5. Regression analysis of formal service costs.
France Germany UK
B 95% CI LL 95% CI UL B 95% CI LL 95% CI UL B 95% CI LL 95% CI UL
PSP strata
1 20.034 20.39 0.32 0.21 20.11 0.53 0.053 20.34 0.45
Age 0.007 20.0094 0.023 0.012 20.011 0.034 20.0035 20.032 0.025
Female gender
2 0.35 0.093 0.61 0.28 20.076 0.63 20.057 20.34 0.22
Duration of disease 20.0038 20.076 0.069 20.056 20.12 0.011 20.0033 20.1 0.096
Secondary education
3 0.27 20.049 0.6 0.036 20.37 0.44 20.12 20.51 0.28
Further education
3 0.63 0.24 1 20.13 20.59 0.34 0.36 20.12 0.85
University education
3 0.23 20.19 0.64 20.03 20.35 0.29 20.16 20.84 0.51
PPS score 0.019 0.013 0.025 0.017 0.012 0.022 0.017 0.012 0.023
MMSE 28–30
4 0.13 20.13 0.39 0.48 0.099 0.87 20.26 20.66 0.14
Unpaid care costs
5 20.012 20.015 20.0092 20.011 20.018 20.0047 20.011 20.018 20.046
1compared to MSA strata,
2compared to males,
3compared to illiterate or primary education only,
4compared to MMSE score 0–27,
5in J000s.
doi:10.1371/journal.pone.0024369.t005
Table 6. Regression analysis of unpaid care costs.
France Germany UK
B 95% CI LL 95% CI UL B 95% CI LL 95% CI UL B 95% CI LL 95% CI UL
PSP strata
1 20.34 20.68 20.0057 0.058 20.19 0.31 0.12 20.3 0.54
Age 0.015 20.013 0.042 0.015 20.003 0.032 0.0089 20.016 0.033
Female
gender
2
20.25 20.61 0.11 0.063 20.081 0.21 20.4 20.6 20.2
Duration of
disease
20.011 20.12 0.1 0.0066 20.048 0.061 0.0064 20.047 0.06
Secondary
education
3
20.34 20.68 20.0038 0.11 20.32 0.54 20.48 20.7 20.26
Further
education
3
20.68 21.51 0.14 0.051 20.52 0.62 20.41 20.95 0.13
University
education
3
20.37 20.8 0.06 20.11 20.53 0.3 21.2 21.8 20.62
PPS score 0.016 0.0063 0.026 0.022 0.016 0.028 0.013 0.0063 0.02
MMSE 28–30
4 0.045 20.37 0.46 0.19 20.15 0.52 20.28 20.64 0.083
Formal care
costs
5
20.037 20.056 20.018 20.041 20.072 20.009 20.035 20.047 20.024
1compared to MSA strata,
2compared to males,
3compared to illiterate or primary education only,
4compared to MMSE score 0–27,
5in J000s.
doi:10.1371/journal.pone.0024369.t006
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low). Finally, the regression models attempted to identify
predictors of cost, but clearly some patient characteristics that
could have influenced cost would have been unmeasured.
In conclusion, these results show PSP and MSA to have
substantial economic costs, which reveals the many care inputs
that these patients require. Costs are appropriately related to
indicators of illness severity. Of great importance is the input
provided by unpaid carers (family and friends). Costs are
significantly associated with symptom severity and if this can be
modified then substantial reductions may be realised.
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